Keratoconus Clinical Trial
Official title:
Use of Gamma-Irradiated Preserved Corneal Tissue to Treat Keratoconus
Verified date | November 2022 |
Source | Cornea and Laser Eye Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study objective is to evaluate the outcomes of placing gamma-irradiated corneal tissue (VisionGraft, CorneaGen, USA) within the cornea of patients with keratoconus, a procedure called Corneal Tissue Addition for Keratoconus (CTAK).
Status | Active, not recruiting |
Enrollment | 10 |
Est. completion date | November 1, 2023 |
Est. primary completion date | June 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least 18 years of age, male or female, of any race - Provide written consent and sign a HIPAA form - Willingness and ability to follow all instructions and comply with schedule for follow-up visits - For females: must not be pregnant - Having topographic evidence of keratoconus which is graded as moderate or severe keratoconus defined as the following: - Moderate Keratoconus: Axial topography consistent with keratoconus, Maximum keratometry on Pentacam greater than or equal to 51.01 D - Severe Keratoconus: Axial topography consistent with keratoconus with marked areas of steepening, Maximum keratometry on Pentacam greater than or equal to 56.01 D - Presence of central or inferior steepening on the Pentacam map - BSCVA less than or equal to 20/25 - Contact lens wearers only: remove contact lenses one week prior to the screening refraction Exclusion Criteria: - Contraindications, sensitivity or known allergy to the use of the test article(s) or their components - If female, be pregnant - Eyes classified as either normal, atypical normal, keratoconus suspect or mild keratoconus on the severity grading scheme - Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example: a) History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, corneal melt, corneal dystrophy, etc.) - A history of delayed epithelial healing in the eye to be treated - Have used an investigational drug or device within 30 days of the study or be concurrently enrolled in another investigational drug or device study within 30 days of the study |
Country | Name | City | State |
---|---|---|---|
United States | Cornea and Laser Eye Institute, Hersh Vision Group | Teaneck | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Cornea and Laser Eye Institute |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Gamma-Irradiated Preserved Corneal Tissue Inlay | Change in mean keratometry on corneal topography | 6 months | |
Secondary | Gamma Irradiated Preserved Corneal Tissue Inlay | Inferior-Superior (I-S) ratio | 6 months | |
Secondary | Gamma Irradiated Preserved Corneal Tissue Inlay | Manifest refraction | 6 months | |
Secondary | Gamma Irradiated Preserved Corneal Tissue Inlay | Uncorrected distance visual acuity | 6 months | |
Secondary | Gamma Irradiated Preserved Corneal Tissue Inlay | Best spectacle corrected distance visual acuity | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04570020 -
Scleral Lens Fitting Using Wide-Field OCT
|
||
Recruiting |
NCT02921009 -
McNeel Eye Center Corneal Crosslinking Study
|
N/A | |
Terminated |
NCT02762253 -
Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.
|
Phase 2 | |
Completed |
NCT01691651 -
Botulinum Toxin A for the Treatment of Keratoconus
|
N/A | |
Completed |
NCT01527708 -
Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas
|
N/A | |
Completed |
NCT01527721 -
Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus
|
N/A | |
Recruiting |
NCT00841386 -
Treatment of Keratoconus Using Collagen Cross-Linking
|
Phase 2/Phase 3 | |
Completed |
NCT00347074 -
A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients
|
N/A | |
Completed |
NCT03187912 -
Accelerated Corneal Cross-linking With Different Riboflavin Solutions
|
Phase 3 | |
Completed |
NCT00584285 -
Corneal Topographer Fluorescein Patterns
|
||
Completed |
NCT03511495 -
Reliability of Topography Measurements in Keratoconus
|
||
Not yet recruiting |
NCT05395650 -
Cyanocobalamin as Photosensitizing Agent
|
||
Completed |
NCT04418999 -
Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus
|
Early Phase 1 | |
Completed |
NCT05019768 -
Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS
|
N/A | |
Completed |
NCT03235856 -
Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE
|
||
Withdrawn |
NCT01789333 -
Higher Irradiance in Keratoconus Ectasia
|
N/A | |
Completed |
NCT05114928 -
Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
|
||
Completed |
NCT03647046 -
Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
|
N/A | |
Recruiting |
NCT04439552 -
fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
|
||
Recruiting |
NCT06100939 -
Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
|
Phase 3 |